UY30403A1 - Sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]fenil]-2e-2-propenamida - Google Patents

Sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]fenil]-2e-2-propenamida

Info

Publication number
UY30403A1
UY30403A1 UY30403A UY30403A UY30403A1 UY 30403 A1 UY30403 A1 UY 30403A1 UY 30403 A UY30403 A UY 30403A UY 30403 A UY30403 A UY 30403A UY 30403 A1 UY30403 A1 UY 30403A1
Authority
UY
Uruguay
Prior art keywords
methyl
propenamide
indol
phenyl
salts
Prior art date
Application number
UY30403A
Other languages
English (en)
Inventor
Frank Stowasser
Joel Slade
Dimitris Papoutsakis
Joginder S Bajwa
Murat Acemoglu
Piotr H Karpinski
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38564366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY30403(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY30403A1 publication Critical patent/UY30403A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se preparan y se caracterizan sales de N-hidroxi-3-[4-[[[2-(2-metil-11H-indol-3-il)etil]amino]metil]fenil]-2 E-2-propenamida.
UY30403A 2006-06-12 2007-06-11 Sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]fenil]-2e-2-propenamida UY30403A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80452306P 2006-06-12 2006-06-12
US86999306P 2006-12-14 2006-12-14

Publications (1)

Publication Number Publication Date
UY30403A1 true UY30403A1 (es) 2008-01-31

Family

ID=38564366

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30403A UY30403A1 (es) 2006-06-12 2007-06-11 Sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]fenil]-2e-2-propenamida

Country Status (38)

Country Link
US (3) US20090197936A1 (es)
EP (1) EP2032531B1 (es)
JP (2) JP2009540005A (es)
KR (2) KR101629352B1 (es)
AR (1) AR061298A1 (es)
AU (1) AU2007257962B2 (es)
BR (1) BRPI0712771A2 (es)
CA (1) CA2654439C (es)
CL (1) CL2007001692A1 (es)
CR (1) CR10439A (es)
DK (1) DK2032531T3 (es)
EA (1) EA015212B1 (es)
EC (1) ECSP088979A (es)
ES (1) ES2570934T3 (es)
GE (1) GEP20105125B (es)
GT (1) GT200800279A (es)
HK (1) HK1126496A1 (es)
HN (1) HN2008001859A (es)
HR (1) HRP20160291T1 (es)
HU (1) HUE027126T2 (es)
IL (1) IL195087A (es)
JO (1) JO3138B1 (es)
MA (1) MA30563B1 (es)
ME (1) ME00531B (es)
MX (1) MX2008015901A (es)
MY (1) MY147345A (es)
NO (1) NO341871B1 (es)
NZ (1) NZ572547A (es)
PE (1) PE20080937A1 (es)
PL (1) PL2032531T3 (es)
RS (1) RS54640B1 (es)
SI (1) SI2032531T1 (es)
SM (1) SMP200900002B (es)
SV (1) SV2008003126A (es)
TN (1) TNSN08501A1 (es)
TW (1) TWI409254B (es)
UY (1) UY30403A1 (es)
WO (1) WO2007146715A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0712993A2 (pt) 2006-06-12 2012-04-17 Novartis Ag polimorfos de n-hidróxi-3-[4[[[2-(2-metil-1h-indol-3-il) etil]amino]metil]fenil]-2e-2-propenamida
US20100292291A1 (en) * 2007-01-10 2010-11-18 Thitiwan Buranachokpaisan Formulations of deacetylase inhibitors
US8519002B2 (en) 2008-04-07 2013-08-27 Takeda Pharmaceuticals U.S.A., Inc. Colchicine solid complex; methods of making; and methods of use thereof
US8003700B2 (en) * 2008-04-07 2011-08-23 Mutual Pharamaceutical Company, Inc. Colchicine solid complex; methods of making; and methods of use thereof
UY32297A (es) * 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
JP5263211B2 (ja) 2010-03-30 2013-08-14 ブラザー工業株式会社 サーバ、プリンタ、及び、サーバのためのコンピュータプログラム
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
MA41544A (fr) 2015-02-19 2017-12-26 Novartis Ag Dosages de panobinostat pour le traitement du myélome multiple
WO2017221163A1 (en) * 2016-06-21 2017-12-28 Alembic Pharmaceuticals Limited Novel salts and polymorphic forms of panobinostat

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US20060270730A1 (en) * 2003-08-07 2006-11-30 Andreas Katopodis Histone deacetylase inhibitors as immunosuppressants
US20050228300A1 (en) * 2004-04-07 2005-10-13 Triage Data Networks Cuffless blood-pressure monitor and accompanying wireless mobile device
BRPI0712993A2 (pt) * 2006-06-12 2012-04-17 Novartis Ag polimorfos de n-hidróxi-3-[4[[[2-(2-metil-1h-indol-3-il) etil]amino]metil]fenil]-2e-2-propenamida
MX2008015899A (es) * 2006-06-12 2009-04-01 Novartis Ag Procedimiento para hacer sales de n-hidroxi-3-[4-[[[2-(2-metil-1h- indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida.

Also Published As

Publication number Publication date
NO341871B1 (no) 2018-02-12
HN2008001859A (es) 2011-07-19
MY147345A (en) 2012-11-30
EP2032531A1 (en) 2009-03-11
TNSN08501A1 (en) 2010-04-14
CL2007001692A1 (es) 2008-05-09
SI2032531T1 (sl) 2016-05-31
NZ572547A (en) 2011-06-30
AU2007257962B2 (en) 2011-06-23
GT200800279A (es) 2010-06-16
KR101629352B1 (ko) 2016-06-13
US20100286409A1 (en) 2010-11-11
HRP20160291T1 (hr) 2016-04-22
TW200815343A (en) 2008-04-01
HUE027126T2 (en) 2016-08-29
NO20090128L (no) 2009-03-11
HK1126496A1 (zh) 2009-09-04
AU2007257962A1 (en) 2007-12-21
ECSP088979A (es) 2009-01-30
PE20080937A1 (es) 2008-08-29
MA30563B1 (fr) 2009-07-01
WO2007146715A1 (en) 2007-12-21
US20110112308A1 (en) 2011-05-12
AR061298A1 (es) 2008-08-20
EA200802382A1 (ru) 2009-06-30
KR20090026281A (ko) 2009-03-12
CR10439A (es) 2009-01-15
JP2009540005A (ja) 2009-11-19
EA015212B1 (ru) 2011-06-30
GEP20105125B (en) 2010-11-25
ES2570934T3 (es) 2016-05-23
JP5771257B2 (ja) 2015-08-26
JP2013256542A (ja) 2013-12-26
RS54640B1 (en) 2016-08-31
TWI409254B (zh) 2013-09-21
KR20150029765A (ko) 2015-03-18
PL2032531T3 (pl) 2016-07-29
SMP200900002B (it) 2010-01-19
IL195087A (en) 2012-10-31
DK2032531T3 (en) 2016-04-11
CA2654439A1 (en) 2007-12-21
IL195087A0 (en) 2009-08-03
SV2008003126A (es) 2011-07-05
SMAP200900002A (it) 2009-01-14
CA2654439C (en) 2014-08-05
JO3138B1 (ar) 2017-09-20
BRPI0712771A2 (pt) 2012-09-25
EP2032531B1 (en) 2016-02-10
US20090197936A1 (en) 2009-08-06
MX2008015901A (es) 2009-01-12
ME00531B (me) 2011-10-10

Similar Documents

Publication Publication Date Title
UY30403A1 (es) Sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]fenil]-2e-2-propenamida
GT200800280A (es) Polimorfo de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida
HK1126495A1 (en) Process for making salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3- yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide n--3-[4-[[[2-(2--1h--3-)]]]]-2e-2-
UA95289C2 (en) Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
CY1117493T1 (el) Αλατα του ν-υδροξυ-3-[4-[[[2-(2-μεθυλ-1η-ινδολ-3-υλ)αιθυλ]αμινο]μεθυλο]φαινυλο]-2ε-2-προπεναμιδιου
DOP2008000069A (es) Sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]]fenil]-2e-2-propenamida.
UA97243C2 (en) Crystalline anhydrous form of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
IL233836A0 (en) Method for preparing n-hydroxy-3-[4-[[[2-(2-methyl-h1-indol-3-yl)ethyl]amino]methyl]phenyl]-e2-2-propanamide
DOP2008000068A (es) Polimorfos de n-hidroxi-3[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20191008